DOACs in the Anticoagulation of Mechanical Valves: A Systematic Review and Future Perspectives.

Tom Langenaeken Arnaud VanoppenFien JanssensLoes TanghePeter VerbruggheFilip RegaBart Meuris

Published in: Journal of clinical medicine (2023)

DOAC use in MHVs has been halted due to the failure of both dabigatran and apixaban in two major clinical trials. However, rivaroxaban was successful in two small clinical trials. Ample research is still needed to explore new valve designs as well as new anticoagulation targets.

Keyphrases

atrial fibrillation
direct oral anticoagulants
clinical trial
venous thromboembolism
aortic valve
phase ii
heart failure
mitral valve
aortic valve replacement
aortic stenosis
open label
double blind
study protocol
transcatheter aortic valve implantation
randomized controlled trial
ejection fraction